GeoVax Labs (GOVX) Stock Forecast and Price Target (2026)

Sell-side coverage follows trading volume and banking relationships, so smaller companies, recent listings, and names outside the major indices often carry little or none. That is the situation with GOVX. It says nothing about the quality of the business, but it does mean there is no informed average to anchor to, and that any single target you find elsewhere is one analyst's model rather than a consensus.

For a pre-revenue biotech like GeoVax, P/E and price-to-sales are not meaningful because there are no profits and no revenue. With a market value of about $2.4 million, below the cash it held at mid-year plus the August raise, the market is pricing in further dilution, listing risk and the cost of a Phase 3 trial rather than the pipeline itself. Cash on hand, burn rate and the Nasdaq outcome matter far more than any multiple.

For the fiscal year ending Dec 2026, the one analyst publishing estimates on GOVX expects earnings of -$5.14 per share.

Estimates are the most widely published forecast there is: many more analysts model a company's earnings than publish a price target on it. They are also revised constantly, and the direction of those revisions into a report is often more informative than the level.

Not a published one. Analyst price targets run to about twelve months, occasionally two years, and the firms covering GOVX do not put out a 2030 number. Anything presenting one is extrapolating a growth rate rather than reporting research, and a figure produced that way tells you about the assumption chosen, not about the company.

What can be said over a long horizon is what the current price already assumes about the business, which is a question the filings answer and a forecast cannot.

That is the more useful frame for a ten-year question. A share price is the market’s estimate of future cash flows discounted to today, so the multiple is already a statement about growth. The long-horizon question is whether GeoVax Labs can deliver what is priced in, and what would have to change for that to break. Both are answerable from the drivers and risks below. A number for 2030 is not.

In short: the drivers cited most often are GEO-MVA and the Mpox Phase 3, GEO-CM04S1 in immunocompromised patients, Gedeptin oncology program. The risk cited most often against it is the risks here are severe and existential.

Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the GOVX is it a buy page. This page deliberately stops at the numbers.